(Press Release)

About the Collaboration and License Agreement

Moorfields Pharmaceuticals and MC2 Biotek have signed a collaboration and license agreement concerning development of novel ophthalmic products addressing unmet clinical needs based on the MC2 Biotek's proprietary PAD™ drug delivery technology.

Moorfields Pharmaceuticals obtains exclusive rights from MC2 Biotek to develop, sell and use ophthalmic "Specials" (unlicensed medicinal ophthalmic products) in specific territories including United Kingdom and Ireland and MC2 Biotek retains all rights to develop
PAD™-based licensed ophthalmic products with support from Moorfields Pharmaceuticals.

 Download the entire Press Release here (PDF)